142 related articles for article (PubMed ID: 26479945)
1. Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.
Chen X; Xu W; Wang K; Mo M; Zhang W; Du L; Yuan X; Xu Y; Wang Y; Shen J
J Med Chem; 2015 Nov; 58(21):8529-41. PubMed ID: 26479945
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.
Chen X; Wang K; Xu W; Ma Q; Chen M; Du L; Mo M; Wang Y; Shen J
J Med Chem; 2016 Mar; 59(6):2674-87. PubMed ID: 26927682
[TBL] [Abstract][Full Text] [Related]
3. Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
Liu Q; Huang F; Yuan X; Wang K; Zou Y; Shen J; Xu Y
J Med Chem; 2017 Dec; 60(24):10231-10244. PubMed ID: 29193967
[TBL] [Abstract][Full Text] [Related]
4. Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors.
Wang K; Xu W; Zhang W; Mo M; Wang Y; Shen J
Bioorg Med Chem Lett; 2013 May; 23(10):2897-901. PubMed ID: 23575276
[TBL] [Abstract][Full Text] [Related]
5. Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA
Woolford AJ; Day PJ; Bénéton V; Berdini V; Coyle JE; Dudit Y; Grondin P; Huet P; Lee LY; Manas ES; McMenamin RL; Murray CW; Page LW; Patel VK; Potvain F; Rich SJ; Sang Y; Somers DO; Trottet L; Wan Z; Zhang X
J Med Chem; 2016 Dec; 59(23):10738-10749. PubMed ID: 27933945
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of imidazole and triazole derivatives as Lp-PLA₂ inhibitors and the unexpected discovery of highly potent quaternary ammonium salts.
Wang K; Xu W; Liu Y; Zhang W; Wang W; Shen J; Wang Y
Bioorg Med Chem Lett; 2013 Mar; 23(5):1187-92. PubMed ID: 23385210
[TBL] [Abstract][Full Text] [Related]
7. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
Riley RF; Corson MA
IDrugs; 2009 Oct; 12(10):648-55. PubMed ID: 19790016
[TBL] [Abstract][Full Text] [Related]
8. Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.
Liu Q; Chen X; Chen W; Yuan X; Su H; Shen J; Xu Y
J Med Chem; 2016 May; 59(10):5115-20. PubMed ID: 27078579
[TBL] [Abstract][Full Text] [Related]
9. Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.
Woolford AJ; Pero JE; Aravapalli S; Berdini V; Coyle JE; Day PJ; Dodson AM; Grondin P; Holding FP; Lee LY; Li P; Manas ES; Marino J; Martin AC; McCleland BW; McMenamin RL; Murray CW; Neipp CE; Page LW; Patel VK; Potvain F; Rich S; Rivero RA; Smith K; Somers DO; Trottet L; Velagaleti R; Williams G; Xie R
J Med Chem; 2016 Jun; 59(11):5356-67. PubMed ID: 27167608
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.
Muthukaman N; Deshmukh S; Tondlekar S; Tambe M; Pisal D; Sarode N; Mhatre S; Chakraborti S; Shah D; Bhosale VM; Kulkarni A; Mahat MYA; Jadhav SB; Gudi GS; Khairatkar-Joshi N; Gharat LA
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3766-3773. PubMed ID: 30340896
[TBL] [Abstract][Full Text] [Related]
11. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
[TBL] [Abstract][Full Text] [Related]
12. Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach.
Huang F; Hu H; Wang K; Peng C; Xu W; Zhang Y; Gao J; Liu Y; Zhou H; Huang R; Li M; Shen J; Xu Y
J Med Chem; 2020 Jul; 63(13):7052-7065. PubMed ID: 32459096
[TBL] [Abstract][Full Text] [Related]
13. (E)-Phenyl- and -heteroaryl-substituted O-benzoyl-(or acyl)oximes as lipoprotein-associated phospholipase A2 inhibitors.
Jeong TS; Kim MJ; Yu H; Kim KS; Choi JK; Kim SS; Lee WS
Bioorg Med Chem Lett; 2005 Mar; 15(5):1525-7. PubMed ID: 15713421
[TBL] [Abstract][Full Text] [Related]
14. Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis.
Chen LZ; Shu HY; Wu J; Yu YL; Ma D; Huang X; Liu MM; Liu XH; Shi JB
Eur J Med Chem; 2021 Mar; 213():113174. PubMed ID: 33515864
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein-associated phospholipase A2: The story continues.
Huang F; Wang K; Shen J
Med Res Rev; 2020 Jan; 40(1):79-134. PubMed ID: 31140638
[TBL] [Abstract][Full Text] [Related]
16. Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.
Jones CD; Andrews DM; Barker AJ; Blades K; Byth KF; Finlay MR; Geh C; Green CP; Johannsen M; Walker M; Weir HM
Bioorg Med Chem Lett; 2008 Dec; 18(24):6486-9. PubMed ID: 18986805
[TBL] [Abstract][Full Text] [Related]
17. Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.
Fauber BP; Gobbi A; Robarge K; Zhou A; Barnard A; Cao J; Deng Y; Eidenschenk C; Everett C; Ganguli A; Hawkins J; Johnson AR; La H; Norman M; Salmon G; Summerhill S; Ouyang W; Tang W; Wong H
Bioorg Med Chem Lett; 2015 Aug; 25(15):2907-12. PubMed ID: 26048793
[TBL] [Abstract][Full Text] [Related]
18. Acyl-CoA:Cholesterol O-acyltransferase (ACAT) inhibitors. 2. 2-(1,3-Dioxan-2-yl)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACAT.
Astles PC; Ashton MJ; Bridge AW; Harris NV; Hart TW; Parrott DP; Porter B; Riddell D; Smith C; Williams RJ
J Med Chem; 1996 Mar; 39(7):1423-32. PubMed ID: 8691472
[TBL] [Abstract][Full Text] [Related]
19. Discovery of bioavailable inhibitors of secretory phospholipase A2.
Blanchard SG; Andrews RC; Brown PJ; Gan LS; Lee FW; Sinhababu AK; Wheeler TN
Pharm Biotechnol; 1998; 11():445-63. PubMed ID: 9760691
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein-associated phospholipase A(2) and atherosclerosis.
Wilensky RL; Macphee CH
Curr Opin Lipidol; 2009 Oct; 20(5):415-20. PubMed ID: 19667981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
